Q-omics provides the consensus-scored TYMSP2 profile across patient tissues and cancer cell-line models. TYMSP2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, TYMSP2 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, TYMSP2 RNA expression shows 6,416 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, PRAD, and STAD as cancer lineages where TYMSP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TYMSP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TYMSP2 survival associations across molecular data types. TYMSP2 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TYMSP2 RNA expression–survival associations across cancer types. High TYMSP2 expression shows unfavorable associations in UCS, ACC, COAD, LUSC and LIHC, but favorable associations in STAD. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for TYMSP2 RNA expression.
This table summarizes TYMSP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for TYMSP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TYMSP2 shows higher tumor expression in PRAD. The PRAD box plot shows higher TYMSP2 RNA expression in tumor versus normal tissue (log2 FC = +0.040, t-test p = .023).
This table shows molecular features associated with TYMSP2 in patient tissues and cancer cell lines. In patient samples, TYMSP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
